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Bending the blood pressure curve down: are we succeeding?
Until just a few decades ago, raised blood pressure was 
regarded as a benign and natural process of ageing 
that did not warrant treatment. In the 1966 edition 
of his textbook Diseases of the Heart,1 the cardiologist 
Charles Friedberg noted that treatment of individuals 
with a blood pressure lower than 200/100 mm Hg 
was not indicated. Since then, the accumulation of a 
large body of evidence on raised blood pressure has 
fundamentally changed clinical practice and health 
policy worldwide. Large-scale epidemiological studies2 
have proven  beyond doubt that long-term exposure to 
raised blood pressure is associated with a substantially 
increased risk of cardiovascular disease, with no 
apparent benign range at any age. An analysis3 of 
population-based studies has quantiﬁ ed the absolute 
burden of blood pressure-associated death and 
disability, showing that raised blood pressure has been 
the leading risk factor for cardiovascular death in every 
region of the world for the past 30 years. Furthermore, 
a range of eﬀ ective and cost-eﬀ ective interventions for 
modifying blood pressure-associated risks have been 
identiﬁ ed.4,5 Not only have these ﬁ ndings changed 
clinical practice and public health but they have 
also become the foundations of global policies; for 
example, WHO’s Global Action Plan for the prevention 
of non-communicable diseases 2013–20 speciﬁ es 
a 25% reduction or containment of the prevalence 
of raised blood pressure as one of its nine voluntary 
targets.6
To what extent have these tremendous achievements 
been eﬀ ective in reducing the burden of raised blood 
pressure so far? The most comprehensive and updated 
answer to this question comes from a report by the NCD 
Risk Factor Collaboration published in The Lancet.7 In 
their study, the authors use population-based surveys 
involving 19·1 million adults to estimate temporal 
trends in mean systolic and diastolic blood pressure and 
the prevalence of raised blood pressure (deﬁ ned as blood 
pressure ≥140 mm Hg systolic or ≥90 mm Hg diastolic) 
from 1975 to 2015 in 200 countries. The collaboration 
found that across all countries, age-standardised mean 
blood pressure has been largely stagnant in men and 
decreased only by about 2·5 mm Hg in women, with 
the change in women occurring before 2000 and no 
apparent change since.
Although at ﬁ rst glance these static trends seem 
disappointing, a closer look at the disaggregated 
results and the comparisons of trends among regions 
and countries reveals several insights that will help to 
refocus our eﬀ orts. One key insight is that substantial 
and continuous reductions in mean blood pressure 
and prevalence of raised blood pressure are achievable, 
as evident from the decreasing trends in the high-
performing, mainly high-income, regions and countries. 
However, the opposing trends in several other, mainly 
low-income and middle-income countries, suggest 
that these countries are unlikely to achieve substantial 
reductions in mean age-standardised population-level 
blood pressure if no additional measures are taken. In 
fact, the report reminds us that even with containment 
of age-standardised blood pressure, the absolute 
number of people aﬀ ected by raised blood pressure is 
likely to continue to grow in low-income and middle-
income countries, mainly because of ageing and 
population growth, which are only partly counteracted 
by other trends.
But what are the key drivers of age-standardised 
blood pressure reductions? Can we learn from the 
success in high-performing countries to bend the 
blood pressure curve down in less successful regions 
and to accelerate reductions in better performing 
regions? The few available long-term national surveys 
that started in the 1950s showed that the reduction 
in mean blood pressure preceded the availability of 
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speciﬁ c interventions targeting it.8,9 This fact suggests 
that a substantial proportion of the change is likely due 
to population-wide interventions. Such interventions 
include some now well established factors such as 
dietary and lifestyle changes, but also some less 
well measured factors such as early-life nutrition, or 
emerging exposures such as indoor temperature, air 
pollution, and noise. In the past three decades, improved 
medical care and widened use of anti-hypertensive 
treatments of proven eﬀ ectiveness have made further 
contributions to blood pressure reductions.8,10 However, 
these treatments remain heavily underused in both rich 
and poor countries,2 calling for alternative models of 
health-care delivery that are less dependent on health-
care professionals and instead make evidence more 
directly accessible to end-consumers.11,12
Eﬀ ective control of raised blood pressure requires 
collaborative, multisectoral, national eﬀ orts to improve 
implementation of available evidence. The failure to 
tackle this issue more decisively will come at a high cost, 
particularly to disadvantaged individuals and societies. 
The clear view of recent achievements, as provided by 
the NCD Risk Factor Collaboration, should help us to 
collectively steer the action plan more eﬀ ectively and 
equitably towards decreasing blood pressure globally.
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